For the first time, we revealed that the expression levels of ET-1 and VEGFA were markedly promoted by miR-200a-3p via targeting MAPK14 in HUVEC, which sheds new light on the underlying mechanism of elevated expression of ET-1 and VEGFA in AIS patients. The gene discussed is MAPK14; the disease is androgen insensitivity syndrome.